PŘEHLEDOVÉ ČLÁNKY JAK inhibice v léčbě zánětlivých revmatických onemocnění 188 | VNITŘNÍ LÉKAŘSTVÍ / Vnitř Lék. 2023;69(3):181-188 / www.casopisvnitrnilekarstvi.cz 12. Taylor PC. Clinical efficacy of launched JAK inhibitors in rheumatoid arthritis. Rheuma‑ tology (Oxford). 2019;58(Suppl 1):i17-i26. 13. Biggioggero M, Becciolini A, Crotti C, Agape E, Favalli EG. Upadacitinib and filgotinib: the role of JAK1 selective inhibition in the treatment of rheumatoid arthritis. Drugs Con‑ text. 2019;8:212595. 14. Šenolt L, Mann H, Závada J, Pavelka K, Vencovský J. Doporučení České revmatolo‑ gické společnosti pro farmakoterapii revmatoidní artritidy 2017. Česká revmatologie. 2017;25(1):3-18. 15. Taylor PC. Clinical efficacy of launched JAK inhibitors in rheumatoid arthritis. Rheuma‑ tology (Oxford). 2019;58(Suppl 1):i17-i26. 16. Strand V, Lee EB, Fleischmann R, et al. Tofacitinib versus methotrexate in rheumatoid arthritis: patient‑reported outcomes from the randomised phase III ORAL Start trial. RMD Open 2016;2:e000308. 17. Keystone EC, Taylor PC, Tanaka Y, et al. Patient‑reported outcomes from a phase 3 stu‑ dy of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analy‑ ses from the RA‑BEAM study. Ann Rheum Dis 2017;76:1853_61. 18. Rubbert‑Roth A, Enejosa J, Pangan AL, et al. Trial of Upadacitinib or Abatacept in Rheu‑ matoid Arthritis. N Engl J Med. 2020 Oct 15;383(16):1511-1521. 19. Ochi S, Sonomoto K, Nakayamada S, Tanaka Y. Preferable outcome of Janus kinase in‑ hibitors for a group of difficult‑to‑treat rheumatoid arthritis patients: from the FIRST Re‑ gistry. Arthritis Res Ther. 2022;24(1):61. 20. Smolen JS, Landewé RBM, Bergstra SA, et al. EULAR recommendations for the manage‑ ment of rheumatoid arthritis with synthetic and biological disease‑modifying antirheu‑ matic drugs: 2022 update. Ann Rheum, DiS. 2023;82(1):3-18. 21. Pombo‑Suarez M, Sanchez‑Piedra C, Gómez‑Reino J, et al. After JAK inhibitor failure: to cycle or to switch, that is the question – data from the JAK‑pot collaboration of regis‑ tries. Ann Rheum, DiS. 2023 Feb;82(2):175-181. 22. Raychaudhuri SK, Abria C, Raychaudhuri SP. Regulatory role of the JAK STAT kinase signalling system on the IL-23/IL-17 cytokine axis in psoriatic arthritis. Ann Rheum, DiS. 2017;76(10):e36. 23. Mease P, Hall S, FitzGerald O, et al. Tofacitinib or Adalimumab versus Placebo for Psori‑ atic Arthritis. N Engl J Med. 2017;377(16):1537-1550. 24. McInnes IB, Anderson JK, Magrey M, et al. Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis. N Engl J Med. 2021;384(13):1227-1239. 25. Gladman D, Rigby W, Azevedo VF, et al. Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors. N Engl J Med. 2017;377(16):1525-1536. 26. Mease PJ, Lertratanakul A, Anderson JK, et al. Upadacitinib for psoriatic arthritis refracto‑ ry to biologics: SELECT‑PsA 2. Ann Rheum, DiS. 2020;80(3):312-20. 27. van der Heijde D, Gladman DD, FitzGerald O, et al. Radiographic Progression According to Baseline C‑reactive Protein Levels and Other Risk Factors in Psoriatic Arthritis Treated with Tofacitinib or Adalimumab. J Rheumatol. 2019;46(9):1089-1096. 28. McInnes IB, Kato K, Magrey M, et al. Upadacitinib in patients with psoriatic arthritis and an inadequate response to non‑biological therapy: 56-week data from the phase 3 SELECT‑PsA 1 study. RMD Open. 2021;7(3):e001838. 29. Gossec L, Baraliakos X, Kerschbaumer A, et al. EULAR recommendations for the manage‑ ment of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum, DiS. 2020;79(6):700-712. 30. Coates LC, Soriano ER, Corp N, et al. GRAPPA Treatment Recommendations domain subcommittees. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. Nat Rev Rheu‑ matol. 2022;18(8):465-479 31. Maksymowych WP, van der Heijde D, Baraliakos X, et al. Tofacitinib is associated with attainment of the minimally important reduction in axial magnetic resonance imaging inflammation in ankylosing spondylitis patients. Rheumatology (Oxford). 2018;57(8):13901399. 32. Deodhar A, Sliwinska‑Stanczyk P, Xu H, et al. Tofacitinib for the treatment of ankylo‑ sing spondylitis: a phase III, randomised, double‑blind, placebo‑controlled study. Ann Rheum, DiS. 2021;80(8):1004-1013. 33. Navarro‑Compán V, Wei JC, Van den Bosch F, et al. Effect of tofacitinib on pain, fati‑ gue, health‑related quality of life and work productivity in patients with active ankylo‑ sing spondylitis: results from a phase III, randomised, double‑blind, placebo‑controlled trial. RMD Open. 2022;8(2):e002253. 34. van der Heijde D, Song IH, Pangan AL, et al. Efficacy and safety of upadacitinib in pa‑ tients with active ankylosing spondylitis (SELECT‑AXIS 1): a multicentre, randomised, double‑blind, placebo‑controlled, phase 2/3 trial. Lancet. 2019 Dec 7;394(10214):2108-2117. 35. van der Heijde D, Deodhar A, Maksymowych WP, et al. Upadacitinib in active anky‑ losing spondylitis: results of the 2-year, double‑blind, placebo‑controlled SELECT‑AXIS 1 study and open‑label extension. RMD Open. 2022;8(2):e002280. 36. Deodhar A, Van den Bosch F, Poddubnyy D, et al. Upadacitinib for the treatment of active non‑radiographic axial spondyloarthritis (SELECT‑AXIS 2): a randomised, double ‑blind, placebo‑controlled, phase 3 trial. Lancet. 2022;400(10349):369-379. 37. Ramiro S, Nikiphorou E, Sepriano A, et al. ASAS‑EULAR recommendations for the ma‑ nagement of axial spondyloarthritis: 2022 update. Ann Rheum, DiS. 2023;82(1):19-34. 38. Harigai M. Growing evidence of the safety of JAK inhibitors in patients with rheuma‑ toid arthritis. Rheumatology (Oxford). 2019;58(Suppl 1):i34-i42. 39. Riley TR, George MD. Risk for infections with glucocorticoids and DMARDs in patients with rheumatoid arthritis. RMD Open. 2021;7(1):e001235. 40. Blum A, Adawi M. Rheumatoid arthritis (RA) and cardiovascular disease. Autoimmun Rev 2019;18(7):679–90. 41. Molander V, Bower H, Frisell T, Askling J. Risk of venous thromboembolism in rheu‑ matoid arthritis, and its association with disease activity: a nationwide cohort study from Sweden. Ann Rheum, DiS. 2021 Feb;80(2):169-175. 42. Ytterberg SR, Bhatt DL, Mikuls TR, et al; ORAL Surveillance Investigators. Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis. N Engl J Med. 2022;386(4):316-326. 43. Desai RJ, Pawar A, Weinblatt ME, Kim SC. Comparative Risk of Venous Thromboem‑ bolism in Rheumatoid Arthritis Patients Receiving Tofacitinib Versus Those Receiving Tumor Necrosis Factor Inhibitors: An Observational Cohort Study. Arthritis Rheumatol. 2019;71(6):892-900. 44. Molander V, Bower H, Frisell T, Delcoigne B, Di Giuseppe D, Askling J; ARTIS study group. Venous thromboembolism with JAK inhibitors and other immune‑modulatory drugs: a Swedish comparative safety study among patients with rheumatoid arthritis. Ann Rheum, DiS. 2023;82(2):189-197. 45. Benucci M, Bernardini P, Coccia C, et al. JAK inhibitors and autoimmune rheumatic di‑ seases. Autoimmun Rev. 2023 Jan 14;22(4):103276. 46. Mease PJ, Deodhar AA, van der Heijde D, et al. Efficacy and safety of selective TYK2 inhibi‑ tor, deucravacitinib, in a phase II trial in psoriatic arthritis. Ann Rheum, DiS. 2022;81(6):815-822. 47. Frisell T, Bower H, Morin M, et al. ARTIS Study group. Safety of biological and targeted synthetic disease‑modifying antirheumatic drugs for rheumatoid arthritis as used in cli‑ nical practice: results from the ARTIS programme. Ann Rheum, DiS. 2023:ard-2022-223762. doi: 10.1136/ard-2022-223762. Epub ahead of print.
RkJQdWJsaXNoZXIy NDA4Mjc=